Skip to content

The dialyzable leukocyte extract activates cervical innate immunity in HPV-infected patients with CIN 1

The dialyzable leukocyte extract activates cervical innate immunity in HPV-infected patients with CIN 1

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN16429164
Enrollment
54
Registered
2016-01-26
Start date
2013-01-02
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low-grade cervical intraepithelial neoplasia (CIN-1) Cancer

Interventions

A total of 54 Mexican women patients with cervical cytological diagnosis of CIN 1 were included in this study. After signing the consent form, patients were evaluated by clinical signs and symptoms. T

Sponsors

National School of Medicine and Homeopathy from National Polytechnic Institute (Mexico).
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Women between 20 and 60 years old with cytological CIN 1 diagnosis.

Exclusion criteria

Exclusion criteria: 1. Women under 20 and over 60 years old 2.Pregnant. 3. Diabetic 4. With autoimmune or infectious diseases 5. Patients with cervicitis under treatment 6. Diagnosed with cervical cancer in situ or invasive 7. With pre-malignant CIN III lesions whose biopsy shows positive margins 8. With pre-malignant lesions of cervical cancer that have been treated with invasive methods

Design outcomes

Primary

MeasureTime frame
1. The colposcopical characteristics of cervical lesions using the iodine test, qualitatively measuring the cervical localization and extension of the lesions 2. Evaluation of clinic signs and symptoms considering the Mexican NOM-014-SSA2-1994 for the prevention, detection, diagnosis, control and treatment of Cu CA Measured before and after one month of treatment.

Secondary

MeasureTime frame
1. Histopathological characterization of biopsies lesions 2. Immunohistochemical evaluation of immunological markers related to innate immune response Measured before and after one month of treatment.

Countries

Mexico

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026